Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPPRESS: SBRT for oligoprogression during first-line chemotherapy in metastatic NSCLC
ChiCTR2400088914Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel and nab-paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-free survival (PFS). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
docetaxelnab-paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400088914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088914.